Advanced Search


Study ID Status Title Patient Level Data
113866 Completed Safety and immunogenicity study of GSK Biologicals’ influenza vaccine GSK2340272A in adults aged 18 to 60 years Study Listed on
113872 Completed A Randomized, Double-Blind, Parallel Group study of ADVAIR™ DISKUS™ 100/50 and FLOVENT™DISKUS™ 100, both twice daily, in a Pediatric Population during the Fall Viral Season. Study Listed on
113874 Completed A Randomized, Double-Blind, Parallel Group, Multicenter Study of the Effects of Fluticasone Propionate/Salmeterol Combination Product 250/50mcg BID (ADVAIR DISKUS™) in Comparison to Salmeterol 50mcg BID (SEREVENT DISKUS™) on the Rate of Exacerbations of COPD Following Hospitalization Study Listed on
113877 Completed A study of fluticasone propionate/salmeterol DISKUS combination product 250/50 mcg twice daily plus tiotropium 18 mcg daily versus placebo DISKUS twice daily plus tiotropium 18 mcg daily on exercise time and physiological parameters in subjects with Chronic Obstructive Pulmonary Disease Study Listed on
113883 Completed Safety and immunogenicity study of GSK Biologicals’ pandemic influenza (H1N1) candidate vaccine (GSK2340274A) in children aged 10 to less than 18 years Study Listed on
113886 Completed A Phase I Dose Escalation Open-Label Safety, Pharmacokinetic and Pharmacodynamic Study to Determine the Recommended Phase II Dose of GSK1120212 Dosed in Combination with GSK2141795
113893 Completed PGx132 lapatinib diarrhea pharmacogenetics in EGF10009, EGF100151, EGF10021, EGF10023, EGF102580, EGF102980, EGF103009, EGF104900, EGF105084, EGF105764, EGF20009, EGF20014, EGF30001 and VEG20007
113896 Completed PGx275 lapatinib liver safety pharmacogenetics in EGF30008
113898 Completed Outcomes Associated with Early or Delayed Maintenance Treatment Post-Chronic Obstructive Pulmonary Disease Exacerbation
113899 Completed Differences in the risk of re-hospitalization and other COPD-related (Chronic Obstructive Pulmonary Disease) exacerbations and costs for patients receiving fluticasone propionate-salmeterol xinafoate combination 250/50mcg (FSC) versus anticholinergics [i.e. tiotropium (TIO) and ipratropium or combination ipratropium-albuterol (IPR) post-hospitalization or ED visit for the treatment of COPD.
113900 Completed Clinical and Economic Burden of Patients with Chronic Obstructive Pulmonary Disease in a Medicaid Population
113901 Completed Outcomes for Chronic Obstructive Pulmonary Disease moderate exacerbators initiating treatment
113902 Completed Chronic Obstructive Pulmonary Disease (COPD)-Related Outcomes and Costs for Patients on Combination Fluticasone Propionate-Salmeterol Xinafoate 250/50mcg versus Anticholinergics in a Comorbid COPD-Depression/Anxiety Population
113903 Completed Observed outcomes associated with fluticasone propionate/salmeterol xinafoate or inhaled corticosteroids in asthma patients
113905 Completed An Open-Label, Flexible-Dose Study of Retigabine Immediate Release (IR) as Adjunctive Therapy to Specified Monotherapy Antiepileptic Treatments in Adults with Partial -Onset Seizures
113907 Completed Benefits of Adherence to 5-alpha reductase inhibitor treatment in Men with Enlarged Prostate: An Assessment of Medicare and Medicaid Patients Using the MarketScan Database
113908 Completed Clinical progression and costs in benign prostatic hyperplasia patients treated with early versus delayed combination therapy
113909 Completed Establishing the Benefits of Adherence to Enlarged Prostate Treatment: A Validation Study Linking Adherence to Outcomes Using the Market Scan Database
113913 Completed A Combination Product of Sumatriptan and Naproxen Sodium versus Single-entity Oral Triptans: An Analysis of Real World Data
113917 Completed Clinical and Economic Burden of Uncontrolled Epilepsy: Analyses from a Medicaid Database and a Private Health Plan Database
113918 Terminated Cost Analysis of Thrombocytopenia Treatment in Patients with Chronic Immune (Idiopathic) Thrombocytopenic Purpura
113922 Completed Outcomes Comparison of Chronic Immune Thrombocytopenic Purpura (ITP) Patients Switched to Eltrombopag and Romiplostim
113929 Completed BRF113929: An Open-Label, Two-Cohort, Multicentre Study of GSK2118436 as a Single Agent in Treatment Naïve and Previously Treated Subjects with BRAF Mutation-Positive Metastatic Melanoma to the Brain
113935 Completed Safety and immunogenicity of GSK Biologicals’ candidate tuberculosis vaccine (692342) when administered to HIV-positive adults living in a Tuberculosis endemic region
113939 Completed Relative bioavailability study between the formulations: Paroxetine 25 mg tablet with controlled release manufactured by GSK Mississauga and Paroxetine 25 mg tablets with controlled release manufactured by SmithKline Beecham (Cidra), fasted administration in healthy volunteers for both genders.



For more information on this register please email

GSK-sponsored clinical studies are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.
GSK-sponsored clinical trials are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party. is a database that provides summary protocol information for ongoing clinical trials. is a search portal provided by the International Federation of Pharamceutical Manufacturers & Associations (IFPMA).

This portal provides a single entry point to search for industry sponsored clinical trials which are on existing registers and databases.

EU Clinical Trials Register is a database of all clinical trials commencing in the European Community from 1 May 2004 onwards. It has been established in accordance with Directive 2001/20/EC.